DCF Advisers LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DCF Advisers LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,900 shares of the biopharmaceutical company's stock after buying an additional 1,150 shares during the period. Regeneron Pharmaceuticals accounts for 3.1% of DCF Advisers LLC's holdings, making the stock its 6th largest position. DCF Advisers LLC's holdings in Regeneron Pharmaceuticals were worth $6,340,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Amundi grew its stake in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after buying an additional 487,489 shares in the last quarter. Proficio Capital Partners LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock worth $156,284,000 after acquiring an additional 219,162 shares during the period. Worldquant Millennium Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $127,489,000. Thrivent Financial for Lutherans increased its stake in Regeneron Pharmaceuticals by 1,272.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 125,194 shares of the biopharmaceutical company's stock valued at $89,179,000 after acquiring an additional 116,074 shares during the last quarter. Finally, KBC Group NV increased its stake in Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock valued at $97,338,000 after acquiring an additional 102,198 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Remove Ads

Regeneron Pharmaceuticals Trading Down 4.1 %

Shares of REGN traded down $26.86 during trading hours on Tuesday, hitting $634.14. 852,346 shares of the stock were exchanged, compared to its average volume of 635,607. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The business has a 50-day moving average of $688.31 and a 200-day moving average of $809.71. The firm has a market capitalization of $69.33 billion, a P/E ratio of 16.57, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the business earned $11.86 EPS. The firm's revenue was up 10.3% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on REGN. TD Cowen reduced their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a report on Tuesday, February 4th. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research report on Friday, January 10th. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 4th. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price for the company. Finally, Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.